Author:
Domínguez-Domínguez Lourdes,Lagarde María,Bisbal Otilia,Matarranz Mariano,Rubio Rafael,Pulido Federico
Reference15 articles.
1. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies;Chen;Gastroenterology,2013
2. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus;Yoshida;Hepatology,2015
3. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect;Poordad;Clin Infect Dis,2015
4. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: a concise review;Burgess;Ann Hepatol,2016
5. Documentos científicos, Infecciones por microorganismos, Hepatitis Virales;Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica,2017